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Aims: Endothelin A receptor (ETAR) and epidermal growth factor receptor (EGFR) cross-talk enhances the
metastatic potential of epithelial ovarian cancer (EOC) cells activating different pathways, including β-
catenin signalling. Here, we evaluated β-catenin as one of ETAR/EGFR downstream pathway in the invasive
behaviour of EOC cells and their therapeutic potential to co-target ETAR and EGFR.
Main methods: The phosphorylation status and interactions of different proteinswere analysed by immunoblotting
and immunoprecipitation. Reporter activity andRT-PCRwas used for evaluation ofβ-catenin transcriptional activity
and gene expression. Functional effects were evaluated by gelatin zymography and cell invasion assays. An ortho-
topic model of metastatic human EOC in mice was used for in vivo studies.
Key findings: In EOC cell lines, ET-1 induced Src-dependent EGFR transactivation, causing tyrosine (Y) phosphor-
ylation of β-catenin at the residue Y654, its dissociation from E-cadherin complexes and the accumulation as an
active form. This pool of Tyr-β-catenin relocalised to the nucleus promoting its transcriptional activity, and the
expression of its target genes, such as MMP-2. At functional level, ET-1 and EGFR circuits enhanced protease ac-
tivity and cell invasion. All these effects were significantly inhibited by the ETAR antagonist, zibotentan, or EGFR
inhibitor, gefitinib, and are completely blocked by co-addition of both drugs. In vivo, zibotentan treatment signif-
icantly inhibited metastases, associated with reduced expression and activation of MMPs and active β-catenin,
especially when combined with gefitinib.
Significance: Altogether these findings provide additional support to the potential use of ETAR and EGFR block-
ade as a new therapeutic opportunity for EOC treatment.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Interference with endothelin-1 (ET-1) signalling pathway has
emerged as a promising strategy for cancer therapy, as this pathway
is frequently activated in a variety of human malignancies, including
epithelial ovarian carcinoma (EOC) (Bagnato and Rosanò, 2008;
Nelson et al., 2003). Actually, ET-1 and the highly specific endothelin
A (ETA) receptor, two members of the endothelin family, have been
reported to induce pleiotropic effects in EOC cells, including cell pro-
liferation, survival, angiogenesis, and invasive activity (Bagnato et al.,
2005). Downstream ETAR activation, ET-1 triggers the activation of
various signaling pathways, including Src family tyrosine kinases,
and epidermal growth factor receptor (EGFR) transactivation (Vacca
et al., 2000; Rosanò et al., 2007a). In particular, sustained autocrine
ET-1/ETAR signalling contributes to induction of epithelial-to-
mesenchymal transition (EMT) (Rosanò et al., 2005), a key processcer Institute, Experimental Re-
, Italy. Tel.: +39 0652662565;
o@ifo.it (L. Rosanò).
Y-NC-ND license.in the development of an aggressive cell phenotype enabling tumour
cells to invade and metastatise (Polyak andWeinberg, 2009). Usually,
the β-catenin turnover is regulated in the cytosol by a large protein
complex including axin, and glycogen synthase kinase-3β (GSK3β),
that prevents its nuclear translocation and promotes its degradation
(Nusse, 2005). In this context, ET-1 can drive inhibition of GSK-3β
to stabilise β-catenin proteins to engage transcriptional programs
that control EMT and increased cell invasion (Rosanò et al., 2005).
Recent studies indicate that β-catenin is a target for various tyrosine
kinases, including EGFR, and its tyrosine phosphorylation may disrupt
the core complexwith E-cadherin and engage β-catenin in its transcrip-
tional activity (Lilien and Balsamo, 2005; Piedra et al., 2003; Roura et al.,
1999). In particular, phosphorylation of tyrosineβ-catenin residue Y654
results in its release from E-cadherin and an increase in TCF-mediated
transcriptional activity (Zeng et al., 2006). As such, enhanced Y654
phosphorylation of β-catenin is believed to increase cell migration
and induce an invasive behaviour of tumour cells (Muller et al., 1999),
although functional evidence for the latter is still lacking.
Previous studies showed that in EOC cells ETAR cooperate with EGFR
to promote mitogenic and invasive signalling pathways (Rosanò et al.,
2007a). Thus, in these cells, β-arrestin-1 is recruited to ETAR to form a
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This complex leads to EGFR transactivation and downstream activation
of Akt andmitogen-activated protein kinase (MAPK), and β-catenin ty-
rosine phosphorylation, thereby mobilising the fraction of β-catenin
that translocates to the nucleus. In parallel and coordinated manner,
β-arrestin-1/ETAR forms a complexwith axin, contributing to inactivate
GSK-3β and to stabilise β-catenin (Rosanò et al., 2009). This is consis-
tent with previous observations that demonstrate that ligand-
dependent activation of different G-protein coupled receptor (GPCR),
such as prostaglandin E(2) or obetastin, induces Akt phosphorylation
via EGFR and MMP activity, through a mechanism involving the associ-
ation with Src and β-arrestin-1 (Buchanan et al., 2006; Alvarez et al.,
2009). The critical role of ET-1 axis in the nuclear translocation of β-
catenin led us to investigate the functional connection between ETAR/
EGFR cross-talk and the β-catenin signalling in order to dissect the mo-
lecular mechanisms following ETAR activation in invasion and metasta-
sis, and to test in vivo the therapeutic efficacy by co-targeting ETAR and
EGFR in this tumour.
Materials and methods
Materials
Clinical grade zibotentan, N-(3-methoxy-5-methylpyrazin-2-yl)-2-
(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulfonamide, and, gefitinib,
4-quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-4-
morpholin propoxy]were kindly provided by AstraZeneca (Macclesfield,
UK). ET-1 was purchased from Peninsula Laboratories (Belmont, CA,
USA).
Cell culture
Human ovarian carcinoma cell line HEY and OVCA 433 were gen-
erously provided by Prof. Giovanni Scambia (Catholic University
School of Medicine, Rome, Italy). The SKOV-3 cell line was obtained
from the American Type Culture Collection (Manassas, VA). Cells
were cultured in RPMI containing 10% foetal calf serum (FCS) and
1% penicillin-streptomycin at 37 °C under 5% CO2-95% air. Cells were
serum-starved by incubation for 24 h in serum-free RPMI. All culture
reagents were from Life Technologies Ltd (Paisley, UK)
Luciferase reporter gene assay
To measure the transcriptional activity of β-catenin, 3×105 cells/
well were transiently cotransfected using LipofectAMINE reagent
(Life Technologies Ltd) with 1 μg pTOP/Flash (Millipore, Milan, Italy)
and 100 ng pCMV-β-galactosidase (Promega Italia, Milan, Italy) vec-
tors. Reporter activity was measured using the Luciferase assay sys-
tem (Promega Italia) and normalised to β-galactosidase activity. The
mean of five independent experiments performed in sextuplicate
was reported.
Immunoblotting and immunoprecipitation
NE-PER nuclear and cytoplasmic extraction reagents Fisher Scientif-
ic (Illkirch Cedex, France)were used to separate cytoplasmic and nucle-
ar fractions. For Western blotting analysis, whole cell lysates or nuclear
fractions or homogenised HEY tumour specimens were resolved by
SDS-PAGE, followed by immunoblotting (IB) using Ab to: anti-
phosphotyrosine (PY-20), E-cadherin (BD Becton Dickinson Italia, Bucci-
nasco (MI), Italy), EGFR, phospho-EGFR (Tyr845), phospho-GSK-3β
(pSer9), GSK-3β, active-β-catenin (Millipore), β-catenin, matrix
metalloprotease-2 (MMP-2), MMP-9, β-actin (Oncogene Research
Products, La Jolla, CA), PCNA (Santa Cruz Biotechnology, Inc., Heidelberg,
Germany), anti-β-catenin (Y86), anti-β-catenin (Y142), anti-β-catenin
(Y654) (Abcam, Cambridge, UK). For immunoprecipitation (IP),precleared whole cell lysates were immunoprecipitated with anti-β-
catenin insolubilised on protein A-Sepharose CL-4B (GE Healthcare,
Milan, Italy). Then, immunoprecipitates were loaded on a 7.5% or 10%
SDS-PAGE and then analysed by SDS/PAGE and IB with different Abs as
before. Blots were developed with the enhanced chemiluminescence
detection system (ECL; GE Healthcare).
RT-PCR
The primers sets were as follows: glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), 5′-GTGAAGGTCGGAGTCAACG-3′ and 5′-GGT-
GAAGACGCCAGTGGACTC-3′; MMP-2, 5′-GGATGATGCCTTTGCTCG-3′
and 5′-ATAGGATGTGCCCTGGAA-3′; Cyclin D1, 5′-CTAATGGAATGGT-
TTGGGAATATCCATGTA-3′ and 5′-AAAGGAACTTATCATCCTGGCAAT-3′.
The cDNA was amplified for 28–35 cycles at 94 °C for 45 s for denatur-
ation step, at specific melting temperature for 45 s for primer annealing
step and for extension step at 72 °C for 45 s (Life Technologies Ltd.). The
PCR was conducted in the automated DNA Thermal Cycler GeneAmp
PCR System 2400 (Bio-Rad Laboratories S.r.l., Milan, Italy). The PCR prod-
ucts were analysed by electrophoresis on a 2% agarose gel containing
ethidium bromide.
Gelatin zymography and MMP activity
Conditioned media from HEY cells or homogenised HEY metasta-
ses specimens were electrophoresed for analysis in 9% SDS-PAGE
gels containing 1 mg/ml gelatin, as previously described (Rosanò et
al., 2007b). Briefly, the gels were washed for 30 min at 22 °C in 2.5%
Triton X-100 and then incubated in 50 mM Tris–HCl (pH 7.6), 1 mM
ZnCl2, and 5 mM CaCl2 for 18 h at 37 °C. After incubation the gels
were stained with 0.2% Coomassie blue.
Gelatinase activities in conditioned media were also determined
by a MMP gelatinase activity assay kit (Millipore) according to the
manufacturer's instructions. The sensitivity of the assay is b5 ng/ml
MMP in the range 10 to 200 ng/ml. The mean of six independent ex-
periments performed in duplicate was reported.
Chemoinvasion assay
Chemoinvasion assay was performed as previously described
(Rosanò et al., 2005). The filters were coated with an even layer of
10 mg/ml Cultrex Basement Membrane Extract Matrigel (Trevigen,
Gaithersburg, MD). After 6 h of incubation at 37 °C, the filters were
removed, stained with Diff-Quick (Dade Behring Inc., Newark, NJ,
USA) and the migrated cells in 10 high-power fields were counted.
The mean of six independent experiments performed in triplicate
was reported.
Metastasis assay
HEY cells (1.8×106) were i.p. injected into female athymic nude
mice (Charles River Laboratories, Milan, Italy), following the guide-
lines for animal experimentation of the Italian Ministry of Health. In
all experiments, each group consisted of 10 mice. One week after in-
jection of cancer cells, one group was treated i.p. for 21 days with
zibotentan (diluted in PBS) (10 mg/kg/day), one group was treated
for 21 days p.o. with gefitinib (125 mg/kg/day, diluted in polyethyl-
ene glycol 400), and one group was treated with zibotentan in combi-
nation with gefitinib. Control animals received the same volume of
polyethylene glycol 400 p.o. as those receiving gefitinib and were
injected with an equal volume of saline solution as animals receiving
zibotentan. At the end of the treatment, mice were sacrificed; the
number of metastases was counted and the removed tumours were
weighed, carefully dissected and snap frozen for IB analysis. All me-
tastases from three independent experiments were included for
final calculation of number of metastatic nodules.
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Data from each experimental group are expressed as the mean±
standard deviation (SD). Multiple group comparisons were per-
formed by one-way analysis of variance (ANOVA), followed by Bartle-
tt's test and Kolmogorov and Smirnov Comparisons Test using
GraphPad InStat version 3.0 for Macintosh (GraphPad Software, San
Diego California, USA). P-valuesb0.05 were considered statistically
significant.
Results
The ETAR/EGFR cross-talk is an upstream event in ET-1-induced β-
catenin tyrosine phosphorylation
In this study we analysed the role of ET-1 on β-catenin tyrosine
phosphorylation in SKOV3, HEY, OVCA 433 ovarian cancer cells. In
agreement with previous data (Vacca et al., 2000; Rosanò et al., 2007a,
2009), we found that, also in SKOV3 cells, exogenous ET-1 induced a
rapid EGFR transactivation on tyrosine 845 (Fig. 1A). Zibotentan, a
specific ETAR antagonist, or gefitinib, an EGFR inhibitor, or PP2, a Src
inhibitor, reduced the ET-1-induced EGFR activation, whereas
combination of zibotentan plus gefitinib completely inhibited EGFR
phosphorylation, confirming that a dual inhibition of EGFR and ETAR
pathways is more effective in controlling the activation of the EGFR
pathway (Fig. 1A). Next, we investigated the putative role of EGFR in
the ET-1-elicited tyrosine phosphorylation of β-catenin. The treatment
with ET-1 for 15 min resulted in a dose-dependent tyrosineFig. 1. ET-1 induces β-catenin tyrosine phosphorylation in EOC cells. A. Lysates of SKOV3 cell
or 1 μM PP2, or combination of zibotentan and gefitinib, were analysed by IB with anti-Y845
ET-1 for 5 min were immunoprecipitated (IP) with anti-β-catenin and immunoblotted (IB)
of HEY, OVCA 433, and SKOV3 cells treated for 15 min with ET-1 (100 nM) were IB with an
cells treated with 100 nM ET-1 for indicated times were IB with an anti-non-serine-threo
(n=3). E. Lysates of HEY cells treated for 5 min with 100 nM ET-1 and/or 1 μM zibotentan
β-catenin, with anti-act β-catenin, anti-pGSK-3β (Ser 9), anti-GSK-3β and with anti-β-ac
with anti-pTyr and anti-E-cadherin. The membranes were re-probed with anti-β-catenin (nphosphorylation of β-catenin with a maximum at the dose of 100 nM
(Fig. 1B). The pattern of tyrosine residue phosphorylation of β-catenin
has been shown to be kinase specific. Activation of tyrosine kinase
FYN, FER and MET leads to phosphorylation at Y142, whereas Y654 or
Y86 can be phosphorylated directly by EGFR (Lilien and Balsamo,
2005). Therefore, we investigated which tyrosine residues could be
phosphorylated by ET-1 treatment. Since three different tyrosine
residues, Y86, Y142 and Y654, play an important role in β-catenin
phosphorylation-mediated stability and transcriptional activity,
immunoblotting analysis was then performed using specific anti-
phosphotyrosine Abs. Interestingly, we observed an enhanced level of
tyrosine phosphorylation using anti-Y654 β-catenin Abs in all three
cell lines (Fig. 1C), whereas no signal was observed using Abs
recognising Y86 or Y142 (data not shown), indicating that Y654
tyrosine residuemay be preferentially phosphorylated upon ET-1 treat-
ment. Moreover, in all cell lines, ET-1 promoted the accumulation of ac-
tive form of β-catenin, demonstrating a functional link between the
increased Y-phospho β-catenin and the active β-catenin in ET-1-
treated cells (Fig. 1D), thus representing a transcriptional active pool.
As shown in Fig. 1E, the specific tyrosine phosphorylation ofβ-catenin
induced by ET-1 was inhibited by zibotentan, as well as gefitinib, treat-
ment and a further inhibition was found in combined treatment, indicat-
ing that Y654 tyrosine residue may be preferentially phosphorylated by
Src-dependent EGFR transactivation induced by ET-1. It is noteworthy
that both tyrosine phosphorylation and inhibition of GSK-3β-dependent
serine/threonine phosphorylation are involved in β-catenin accumula-
tion and transcriptional activation, whereas β-catenin serine/threonine
phosphorylation is required for its degradation (Barker, 2008). Accordings treated with 10 ng/ml EGF, or 100 nM ET-1, and/or 1 μM zibotentan, or 1 μM gefitinib,
-EGFR and anti-EGFR (n=3). B. Lysates of SKOV3 cells treated for the indicated doses of
with anti-pTyr. The membranes were re-probed with anti-β-catenin (n=3). C. Lysates
ti-Y654-β-catenin and anti-β-catenin (n=3). D. Lysates of HEY, OVCA 433 and SKOV3
nine phosphorylated, nonubiquitinated, active (act) β-catenin and with anti-β-actin
, or 1 μM gefitinib, or zibotentan and gefitinib were IB with anti-Y654-β-catenin, anti-
tin (n=3). F. Lysates of HEY cells treated as in C were IP with anti-β-catenin and IB
=3).
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catenin was inhibited by zibotentan, as well as by gefitinib, and the com-
bined treatment led to a significantly greater degree of inhibition than
single drug (Fig. 1E). Moreover, the dual treatment completely inhibited
the ET-1-induced GSK-3β phosphorylation and inactivation, blocking
the degradative pathway. Altogether these results confirmed that the ac-
tivation of EGFR by ET-1 is sufficient to induce the accumulation of β-
catenin by concomitant tyrosine phosphorylation and inhibition of its
degradative pathway, and that a combined inhibition of ETAR and EGFR
pathways is more effective in controlling these effects.
Previous studies have documented that β-catenin tyrosine
phosphorylation causes a lowering of its affinity for E-cadherin and
changes in morphology and mobility (Hudson et al., 2008). By
immunoprecipitation assay, we found that increased tyrosine
phosphorylation of β-catenin in ET-1-treated cells was accompanied
by reduced E-cadherin association with β-catenin compared with
untreated cells, that was inhibited by zibotentan and gefitinib, and
to a greater extent, by the combination of both (Fig. 1F). These results
indicated the ability of ET-1 to induce the relocalisation of β-catenin
from the E-cadherin-bound membrane by promoting its tyrosine
phosphorylation and that EGFR activation is required for this event.Fig. 2. ETAR and EGFR cross-talk regulates β-catenin transcriptional activity and cell invasion
IB with anti-Y-654-β-catenin, anti-PCNA, and anti-β-actin, used as nuclear and cytosolic cont
cells, transiently co-transfected with TOPFlash reporter construct and pCMV-β-galactosidase
and/or zibotentan and gefitinib for 24 h. Data shown are means (SD) of 5 independent exp
MMP-2 and Cyclin D1 mRNA expression was analysed in HEY cells treated for 24 h as in B
treated with ET-1 and/or zibotentan and gefitinib for 48 h. Gelatin zymography was used to
by a MMP gelatinase activity assay kit. Data shown are means (SD) of 3 independent experi
OVCA 433 cells were treated with ET-1 (100 nM), and/or 1 μM zibotentan, and/or 1 μM gefit
assay. Data shown are means (SD) of 6 independent experiments, each done in triplicate; *Effects of ET-1 on β-catenin transcriptional activity and cell invasion
Previous studies have described that β-catenin tyrosine phosphor-
ylation may result in its relocalisation into the nucleus (Lilien and
Balsamo, 2005). Therefore, we hypothesised that ET-1 could induce
EGFR-dependent β-catenin nuclear distribution. As shown in Fig. 2A,
tyrosine phosphorylated β-catenin is almost absent in the nucleus
of untreated cells, while ET-1 stimulation promotes the accumulation
of this form in the nuclear compartment. Moreover, the combined
treatment with zibotentan and gefitinib completely inhibits this
accumulation, suggesting that the ET-1-induced nuclear distribution
of β-catenin is dependent of its EGFR-mediated tyrosine
phosphorylation.
Next, we analysed whether nuclear Y-phospho β-catenin could
exert a transcriptional function through its association with TCF4
transcription factor, regulating the transcription of important
tumour-promoting genes, such as MMP-2, and cyclin D1 (Nusse,
2005). Therefore, we examined the effects of zibotentan and
gefitinib on ET-1-induced β-catenin transcriptional activation. As
shown in Fig. 2B, treatment with ET-1 specifically induced a
significant increase in TCF/LEF transcriptional activity in both HEY. A. Nuclear extracts of HEY cells treated with ET-1 and/or gefinitib and zibotentan were
rols, respectively (n=3). B. β-catenin/TCF transcriptional activity was evaluated in EOC
plasmid, incubated with ET-1 (100 nM), and/or 1 μM zibotentan, and/or 1 μM gefitinib,
eriments; *pb0.001 versus untreated cells (C); **pb0.05 versus ET-1-treated cells. C.
. by RT-PCR. GAPDH expression was used as loading control (n=3). D. HEY cells were
determine the activities of MMP-2 and MMP-9. Lower. MMP activity was also measured
ments; *pb0.001 versus untreated cells; **pb0.01 versus ET-1-treated cells. E. HEY and
inib, and/or zibotentan and gefitinib and cell invasion was measured using an invasion
pb0.001 versus untreated cells (C); **pb0.05 versus ET-1-treated cells.
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effect of ET-1 was significantly inhibited by pretreatment with
zibotentan and gefitinib and further inhibitory effect was observed
in combination treatment (pb0.05 versus ET-1-treated cells). More-
over, RT-PCR confirmed that ET-1 treatment markedly increased the
expression of MMP-2 and cyclin D1, which was partially blocked by
pretreatment with zibotentan or gefitinib and at greater extend in
combination of both, confirming the cross-talk between ET-1 and
EGFR in induction of β-catenin signaling (Fig. 2C). Since the invasive
activity of ET-1 in EOC cells is known to be exerted mainly through
the expression and activation of proteolytic enzymes (Rosanò et al.,
2001), including MMP-2 and MMP-9, which are target genes of β-
catenin, we analysed whether zibotentan and gefitinib could exert
anti-invasive effects through inhibition of MMP-2 and -9. As shown
in Fig. 2D, both gelatin zymography and protease activity measure-
ments demonstrated a significant increase in MMP-2 and MMP-9 ac-
tivity in ET-1-stimulated HEY cells (pb0.001 versus untreated cells),
whereas pretreatment with zibotentan in combination with gefitinib
reduced these effects (pb0.01 versus ET-1-treated cells). Combined
treatment significantly inhibited also ET-1 induced invasion of these
cells (Fig. 2E), thus suggesting that concomitant blockade of the
cross-talk between ETAR and EGFR can control cellular motility by
inhibiting β-catenin signalling.
Effects of combination treatment with zibotentan and gefitinib in
metastatic potential of EOC cells
In order to investigate whether the combined regimen of ziboten-
tan and gefitinib could inhibit metastatic dissemination, we used an
orthotopic model of metastatic human ovarian carcinoma in athymic
immunodeficient mice. This model corresponds to stage III ovarian
cancer, which is the stage at which the majority of patients with ovar-
ian cancer are first treated. We found a widespread dissemination of
tumour cells in control mice, including multiple metastatic nodules
throughout the peritoneum, stomach, duodenum, liver, spleen, and
diaphragm (Fig. 3A).
Conversely, mean metastatic nodules were significantly reduced
in the group treated with zibotentan or gefitinib (pb0.001 versus
mice treated with vehicle) (Fig. 3A). Moreover, the combinedFig. 3. Effect of zibotentan and gefitinib treatments on metastatic potential of ovarian cance
mice were treated for 21 days with vehicle, or with zibotentan (10 mg/kg/day), or with ge
consists of 10 mice. Data shown are means (SD) of 5 independent experiments; *p≤0.001 v
tinib. B. Total lysates obtained from homogenised HEY tumour xenografts treated as in A we
HEY tumour xenografts treated as in A were IB with anti-actin–β-catenin, anti-MMP-2, antregimen of zibotentan and gefitinib resulted in a further reduction
in the number of metastatic nodules compared with single treatment
(pb0.005 versus mice treated with zibotentan or gefitinib) (Fig. 3A).
To analyse whether zibotentan and gefitinib could exert anti-
metastastic effects also through inhibition of MMPs, we performed
gelatin zymography analysis performed on HEY metastatic nodules
of control and treated animals. According with reduction of the num-
ber of intra-abdominal metastases, the gelatinolityc activities of
MMP-2 and -9 found in the control group was significantly reduced
in the zibotentan-treated group and almost completely inhibited in
the zibotentan plus gefitinib-treated group, (Fig. 3B), suggesting
that the anti-invasive mechanism of zibotentan might mainly involve
inhibition of MMP activation, that can be amplified trough the combi-
nation with gefitinib. In parallel, Western blotting analyses on the
same tissues confirmed a marked decrease of MMP expression in
zibotentan-treated mice and especially in zibotentan plus gefitinib-
treated mice compared with control (Fig. 3C).
Based on our previous results showing an ETAR-dependent activa-
tion β-catenin pathway in promoting metastatic ability of ovarian
(Rosanò et al., 2009), we also evaluated the pattern of expression of
active β-catenin in the same metastatic nodules. We observed a
strong decrease in the active β-catenin expression in the metastatic
nodules derived from zibotentan-treated mice when compared to
control, that reached almost complete loss of expression in the
group of zibotentan plus gefitinib-treated mice (Fig. 3C). These re-
sults further support the role of ETAR/EGFR cross-talk to promote
the metastatic behaviour of ovarian cancer cells and harbour the effi-
cacy of targeting both receptors to reduce cancer metastasis in vivo.
Discussion
Drug development strategies include the evaluation of new drug
combinations of targeted agents, such as with small molecules,
which may have improved efficacy compared with single agents.
EOC is a leading cause of death from gynaecological malignancy
(Jemal et al., 2007). Ovarian cancer metastases are frequently estab-
lished by a unique microenvironmental niche comprised of tumour
and inflammatory cells, along with a wide range of bioactive soluble
factors, including ET-1 (Khan et al., 2010; Barbolina et al., 2009;r cells. A. HEY cells were injected i.p. into nude mice and one week after cell injection,
fitinib (125 mg/kg/day), or with a combination of zibotentan and gefitinib. Each group
ersus mice treated with vehicle; **pb0.005 versus mice treated with zibotentan or gefi-
re subjected to gelatin zymography (n=3). C. Total lysates obtained from homogenised
i-MMP-9 and with anti-β-actin for internal control (n=3).
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the role of ET-1/ETAR axis in tumour progression and metastasis in
preclinical studies suggests that modulating the activity of the ETAR
offers opportunity for targeted intervention in patients with meta-
static disease (Rosanò et al., 2007a,b, 2009). In the present work, we
describe a functional interaction between ETAR and EGFR to promote
the ET-1-elicited biological subroutines, involving β-catenin signaling
through its tyrosine phosphorylation, and to sustain ovarian cancer
invasive and metastatic growth, having significant implications for
the control of metastatic ovarian cancer.
We provide evidences that, upon ET-1 stimulation, activated EGFR
associates and phosphorylates β-catenin, which in turn initiates the
dissociation from E-cadherin, its redistribution to the nucleus and, ul-
timately, the formation of the transcriptional active β-catenin/TCF4
complex. The activation of β-catenin signaling by the ETAR/EGFR
cross-talk is also responsible for the expression and activation of met-
astatic genes, such as MMP-2, and enhanced cell invasion. Finally, the
concomitant blockade of ETAR and EGFR in vivo completely reduces
the number of metastasis, associated with downregulation of active
β-catenin and MMP activity.
β-catenin is a pivotal molecule of the Wnt signalling pathway, in-
volved in regulation of developmental and oncogenic processes as
well as in intercellular adhesion. The oncogenic properties of β-
catenin signaling stem from alteration in phosphorylation-dependent
protein degradation and subcellular localisation of β-catenin from cell
membrane to the nucleus, where it binds to TCF and facilitates tran-
scription of target genes that encode effectors facilitating tumour pro-
gression. β-catenin complex with the cytoplasmic tail of E-cadherin is
mostly regulated by phosphorylation of the Y654 tyrosine residue,
which induces β-catenin dissociation from E-cadherin by several tyro-
sine kinase receptors, such as EGFR (Lilien and Balsamo, 2005;
Brembeck et al., 2006).Most importantly, completely unrelated cell sur-
face receptors, such as GPCRs, are able to activate tyrosine kinase recep-
tors that, in turn, promote β-catenin tyrosine phosphorylation and
subsequently translocation into the nucleus (Fischer et al., 2004), there-
by influencing the invasive outcomes in cancer cells. These findings
strongly suggest that EOC cells, as well as stromal cells, in the tumour
microenvironment, by secreting ET-1, can activate EGFR expressed at
the plasma membrane cells resulting in increased tyrosine phosphory-
lation ofβ-catenin, affecting its functions in cell adhesion and signalling.
In particular, we found that ET-1-dependent phosphorylation of β-
catenin residue Y654 by EGFR results in its release from E-cadherin
and an increase in TCF-mediated transcriptional activity, suggesting
that β-catenin Y654 phosphorylation balances its role between cell ad-
hesion and Wnt signalling. Recently, data, obtained using a conditional
knock-in mouse model in which the phospho-mimicking Y654E modi-
fication in the endogenous β-catenin gene was introduced, uncovered
a newmechanism inwhich phosphorylation of β-catenin at Y654 intro-
duces a conformational change affecting protein-protein interactions.
This reduces its affinity for the adherens complex, while it is simulta-
neously more accessible for additional phosphorylation, which in-
creases the recruitment of proteins involved in the transcription
machinery (van Veelen et al., 2011). Moreover, we found that enhanced
ET-1-induced Y654 phosphorylation of β-catenin is associated to
increased invasive behaviour of tumour cells. Consistent with this, it
has been demonstrated that MMP genes are under the influence of
the transcriptional activity of β-catenin, as β-catenin responsive ele-
ments are reported to be present in the MMP genes (Munshi and
Stack, 2006). Thus, ETAR/EGFR related activation ofβ-catenin represents
a central node of ET-1 axis where different signals converge to regulate
metastatic process. Interestingly, our in vitro results showed that the in-
hibition of ETAR and EGFR, with zibotentan or gefitinib, effectively
blocked the ET-1-induced β-catenin tyrosine phosphorylation and tran-
scriptional activity, and downstream cell invasion. Moreover, these
activities were substantially abolished by simultaneous administration
of zibotentan and gefitinib, further supporting the possible use of thecombination of targeted therapies in EOC, to block the interrelated
ETAR/EGFR pathway in the acquisition of invasive and metastatic
phenotypes.
Previous preclinical studies focused to study ETAR for targeted ther-
apy in this tumour demonstrated that blockade of ETARwith zibotentan
impedes in vitro and in vivo the ETAR-driven tumour cell proliferation,
angiogenesis, invasion, and inhibition of apoptosis (Rosanò et al.,
2003, 2007b). The coadministration of gefitinib enhanced the efficacy
of zibotentan in a subcutaneousmodel of EOC, leading to partial or com-
plete tumour regression, associatedwith decreased vascularisation, and
expression of cancer progression relatedmarkers (Rosanò et al., 2007a).
Here, to better define the antimetastatic ability of zibotentan in combi-
nation with gefitinib in human EOC, we conducted this study using the
orthotopic model of metastatic human EOC. This is the first report
showing that the concomitant blockade of ETAR and EGFR inhibited tu-
mour cells from disseminating to internal organs to a greater degree
than single-agent therapy. Strikingly, this combination is also effective
against the proteolytic activity and the invasiveness of ovarian tumours.
At translation level, a novel and promising cancer treatment strategy
could be the incorporation of ETAR blockade with other molecular-
targeted drugs to therapeutically overcome compensatory mechanisms
of escape, which could provide an advantage to metastatisation.
Conclusions
Clinical and experimental studies have identified the final step of
ovarian cancer progression, metastatic colonisation of peritoneum,
as a tractable therapeutic target (Barbolina et al., 2009; Khan et al.,
2010). Molecular characterisation of ovarian cancer has led to the
identification of potential molecular targets for new treatments, in-
cluding ETAR. Since the results of the clinical trials of zibotentan as a
monotherapy and in combination with cytotoxic drugs to interrupt
the ET-axis has met with mixed levels of success, in which the prom-
ising delay in disease progression did not translate into an overall-
survival benefit (Bagnato et al., 2011), the discovery of new biologic
co-targeted agents is an exciting new chapter in the treatment of gy-
necologic malignancies. Based on the cooperative antimetastatic ac-
tivity of ETAR and EGFR inhibitors in our preclinical model, we
suggest that substances targeting these systems should be considered
as a new tool for treatment of ovarian cancer.
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